Navigation Links
Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
Date:11/12/2008

DOYLESTOWN, Pa., Nov. 12 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., a wholly-owned subsidiary of The Quigley Corporation (Nasdaq: QGLY) announced today that the last subject in the Phase IIb Study is scheduled to complete treatment on November 25, 2008. This will effectively move the study to the final stage of data collection, evaluation and study conclusions. The Company, after collecting all the patient information from 21 Study centers and conferring with its panel of experts on the data, will draft and report study conclusions, as soon they are available.

The Phase IIb study is designed to evaluate the safety and efficacy of QR-333, a unique topical formulation designed to offer physicians and patients an effective, easy to administer, safe treatment for diabetic peripheral neuropathy with little to no side effects. To date there is no fully effective treatment for diabetic neuropathy. Current treatment options are limited to products such as NSAIDs, analgesics, anticonvulsants, antidepressants, etc., which are often not well tolerated by patients.

The Company believes that a safe and efficacious topical product, if approved by the FDA, could be a "first line" treatment for diabetic peripheral neuropathy and possibly could develop a significant market position in a growing therapeutic category currently dominated by systemic therapies.

Currently in the United States, there are approximately 20,000,000 people with diabetes. Of this population, nearly one half has or will develop symptoms of peripheral neuropathy. Diabetic neuropathy is among the most common complications of diabetes, resulting in pain and numbness, which affects the patient's sleep, functioning and well being. The pain is often accompanied by
'/>"/>

SOURCE Quigley Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
2. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
3. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
4. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
5. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
6. Waterfront Media Announces Everyday Health Network is Number One Online Health Destination : First time in ten years comScore Media Metrix names a new leader in online health
7. Hologic Announces Fourth Quarter and Fiscal 2008 Operating Results
8. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
9. International Isotopes Inc. Announces Third Quarter and Nine Months 2008 Financial Results
10. Prime Companies Announces Launch of Consumer Dental Service Software
11. WebMD Announces 2008 Health Heroes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2012)... 2012, SAN FRANCISCO Prior treatment with inhaled ... community acquired pneumonia (CAP) is associated with a ... to a new study from researchers in Spain. ... pleural effusion (excess fluid that accumulates between the ... the lungs) that arises as a result of ...
(Date:5/23/2012)... ROCHESTER, Minn. -- Mayo Clinic researchers will present ... other urological research at the annual meeting of ... Mayo Clinic urologists will also be available to ... , Mayo Clinic studies that will be presented ... negative impact on overall survival from post-prostate surgery ...
(Date:5/22/2012)... trials (RCTs) are critical for determining effectiveness of ... scant support for these studies compared with other ... ( Canadian Medical Association Journal ). , ... Sciences, Hamilton, Ontario, with Dr. John Cairns, University ... appendix that Canada should provide better financial support ...
(Date:5/22/2012)... The University of Kentucky Markey Cancer Center has ... blood and bone marrow disease often caused by chemotherapy ... Edward P. Evans Foundation, along with a $1.25 million ... , The Evans Foundation grant will fund five research ... one at Cincinnati Children,s Hospital, and one at the ...
(Date:5/22/2012)... 2012) -- Researchers at Barrow Neurological Institute at ... how and why the public perceives some magic ... implications in military tactics, marketing and sports. , ... Neuroscience, and Stephen Macknik, PhD, of Barrow,s Laboratory ... research into magic and illusions. Their most recent ...
Breaking Medicine News(10 mins):Health News:Long-term ICS use reduces pleural effusion in patients with CAP 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4Health News:Canada should significantly increase its funding of randomized clinical trials 2Health News:Markey receives $6.25 million to study deadly blood and bone marrow disease 2Health News:Markey receives $6.25 million to study deadly blood and bone marrow disease 3Health News:Barrow researchers use magic for discoveries 2
... commitment to cover the uninsured was clear today, as,thousands ... the,uninsured, and voted to study the impact of free ... and to study the tax treatment of,health savings accounts., ... need to find ways to care for,those in need ...
... Pain and Improves Functioning in Fibromyalgia Patients, ... Food and Drug,Administration (FDA) has approved Cymbalta(R) ... chronic widespread pain disorder, Eli Lilly,and Company ... is the first serotonin-,norepinephrine reuptake inhibitor with ...
... increase risk of death among elderly patients with dementia, ... -- The U.S. Food and Drug Administration is cautioning ... the death risk of seniors with dementia. , Doctors ... demented patients. , But from now on these older, ...
... number of hot flashes that they experience by more than ... verbal memory, according to a study by researchers at the ... online and will appear in the September/October issue of the ... to explore the relationship between objectively measured hot flashes and ...
... The American,Association for Homecare (AAHomecare) applauded congressional ... will delay for at least 18 months the,controversial ... equipment and services. The bill, H.R. 6252, is ... 2008.", The competitive acquisition or "competitive bidding" ...
... and pharmaceuticals were important to medicine in the 19th,& 20th ... century,and biofeedback is an important component of Behavioral Medicine, Dr. ... Basmajian, Member of the ... the World,s Leading Sport,Psychologists that trained Canada,s top Olympic athletes ...
Other Medicine News:Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 2Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 3Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 4Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 5Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 6Health News:FDA Orders Warning Label on Older Antipsychotics 2Health News:FDA Orders Warning Label on Older Antipsychotics 3Health News:Hot flashes underreported and linked to forgetfulness 2Health News:American Association for Homecare Applauds Bill to Delay the Flawed Medicare Bidding Program for Home Medical Equipment 2Health News:American Association for Homecare Applauds Bill to Delay the Flawed Medicare Bidding Program for Home Medical Equipment 3Health News:Biofeedback Workshops & Distance Learning Offer Credits and Training Options 2
(Date:5/23/2012)... -- TriReme Medical, Inc. (TMI) today announced approval by ... Glider™ PTCA Catheter, indicated for treating the stenotic portion ... perfusion. Glider™ is the world,s only torqueable ... art tip technology, Glider™ is designed to perform, even ... in an ultra short balloon length of 4mm designed ...
(Date:5/23/2012)... LONDON, May 23, 2012 ... of individuals surveyed reported temperature excursions in 6% ... Temperature excursions of pharmaceutical products can not only ... lives. Cold Chain IQ presents a ... chain for clinical and commercial products and leading ...
(Date:5/22/2012)...  Prodigy Generics, a division of Prodigy Health ... is the generic equivalent of the branded drug ... eVenus Pharmaceutical Laboratories to develop a portfolio of ... ANDAs being developed through the partnership that will ... U.S. injectable market, which has experienced record levels ...
Breaking Medicine Technology:TriReme Medical, Inc. Receives FDA Approval for Glider™ PTCA Catheter 2New 2012 Cold Chain Report Examines the Extent of Temperature Excursions During the Handling of Temperature-Sensitive Pharmaceutical Shipments 2QImaging Introduces 64 Bit QCam Driver 15375 1QImaging Introduces 64 Bit QCam Driver 15375 2IPS Appoints Dave Wareheim as Bioprocess Subject Matter Expert 15373 1IPS Appoints Dave Wareheim as Bioprocess Subject Matter Expert 15373 2IPS Appoints Dave Wareheim as Bioprocess Subject Matter Expert 15373 3New Pick Up Filters Remove Particles at The Source 64919 1New Pick Up Filters Remove Particles at The Source 64919 2
Micro-Kerrison Laminectomie Rongeur and Stella Punch, golden springs, with ejector. 18 cm - 7 1/8, very delicate, narrow footplate, small handle, 40 up-cutting, jaws 2 mm wide....
... Boss Anteater Titanium Microdisectomy System ... discs provides for less invasive procedures ... lumbar microdisectomy, decompression, laminoplasty, forminal HNP. ... low profile, unobstructed retraction capabilities and ...
... OSV II Smart ValveTM, Hakim, ... the intelligent choice for meeting ... shunting. Automatic pressure response causes ... to the conditions present, eliminating ...
Codman Hakim Programmable micro with Rickham Reservoir offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition will often ch...
Medicine Products: